220P Impact of time to progression (TTP) on CDK4/6 inhibitor (CDK4/6i) therapy on progression-free survival (PFS) in HR+/HER2-/PIK3CA-mutated advanced breast cancer (aBC) patients (pts) treated with alpelisib plus endocrine therapy (ALP+ET): An exploratory analysis of the METALLICA trial
Llombart-Cussarc, A., García, J.M. Pérez, Borrego, M. Ruiz, Ortega, P. Tolosa, Ortega, A. Fernandez, Blanch, S., Ribate, A. Urruticochea, López-Barajas, I. Blancas, Manich, C. Saura, Ciruelos, E.M., Gómez-Peralta, F., Vicente, S.V. García, García-Mosquera, J.J., Jiménez-Cortegana, C., Morató, J. Rodríguez, Mina, L., Cordero, M. Sampayo, Cortés, J.
Published in ESMO open (01.05.2024)
Published in ESMO open (01.05.2024)
Get full text
Journal Article